Histone acetylation in reproductive organs: Significance of histone deacetylase inhibitors in gene transcription

10.1038/38444

10.1016/S0959-437X(98)80134-2

Stahl BD, 2000, The language of covalent histone modifications, Nature, 403, 41, 10.1038/47412

10.1016/S0959-437X(02)00279-4

10.1038/38664

10.1006/excr.2001.5187

10.1038/35106079

10.1074/jbc.M101287200

10.1093/oxfordjournals.jbchem.a021347

10.1016/S0021-9258(17)44885-X

10.1073/pnas.95.6.3003

Kelly WK, 2003, Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously, Clin Cancer Res, 9, 3578

10.1074/jbc.M100206200

Butler LM, 2001, Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase, Clin Cancer Res, 7, 962

10.1038/sj.onc.1202564

10.1073/pnas.93.23.13143

Kijima M, 1993, Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase, J Biol Chem, 268, 22429, 10.1016/S0021-9258(18)41547-5

10.1210/jc.86.2.834

Sandor V, 2002, Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms, Clin Cancer Res, 8, 718

10.1073/pnas.96.8.4592

Kraker AJ, 2003, Modulation of histone acetylation by [4‐(acetylamino)‐N‐(2‐amino‐phenyl) benzamide] in HCT‐8 colon carcinoma, Mol Cancer Ther, 2, 401

10.1097/00130404-200301000-00010

Van Lint C, 1996, The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation, Gene Expr, 5, 243

10.1093/jnci/92.15.1210

10.1074/jbc.M211715200

10.1038/sj.onc.1203963

10.1038/43710

Strait KA, 2002, Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins, Mol Cancer Ther, 1, 1181

10.1158/1078-0432.CCR-03-0100

10.1074/jbc.M106688200

10.1038/sj.onc.1206875

Fu Y, 2003, Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells, Mol Cancer Res, 1, 569

10.1074/jbc.M213093200

10.1073/pnas.73.3.862

Munster PN, 2001, The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells, Cancer Res, 61, 8492

10.1016/j.ceb.2003.11.001

Kitazono M, 2001, Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228, Cancer Res, 61, 6328

10.1074/jbc.M111011200

10.1139/o03-077

10.1016/S0168-8278(02)00275-1

10.1038/86507

10.1517/13543784.10.8.1571

10.1161/01.RES.0000037983.07158.B1

10.1016/S0006-291X(02)02787-0

10.1074/jbc.M209570200

10.1074/jbc.M108364200

10.1038/sj.onc.1207315

10.1677/joe.0.1790041

10.1210/en.2003-0940

10.1083/jcb.200303047

10.1002/j.1939-4640.2004.tb02859.x

Nervi C, 2001, Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity, Cancer Res, 61, 1247

10.1073/pnas.1633616100